{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Anomalies&page=26",
    "query": {
      "condition": "Gastrointestinal Anomalies",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 1323,
    "total_pages": 133,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Anomalies&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Anomalies&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T11:53:48.261Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02480114",
      "title": "Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Malignant Head and Neck Neoplasm",
        "Mucositis",
        "Radiation-Induced Disorder"
      ],
      "interventions": [
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Pain Therapy",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Oxycodone/Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Hydrocodone/Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Fentanyl",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Magic Mouthwash",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2015-07",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02480114"
    },
    {
      "nct_id": "NCT05643495",
      "title": "A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha-1 Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "VX-864",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 14,
      "start_date": "2023-02-23",
      "completion_date": "2024-08-19",
      "has_results": true,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 10,
      "location_summary": "Gainesville, Florida • Orlando, Florida • Iowa City, Iowa + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Hannibal",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05643495"
    },
    {
      "nct_id": "NCT02275936",
      "title": "Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "N91115",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nivalis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2015-02",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275936"
    },
    {
      "nct_id": "NCT02378467",
      "title": "Saline Hypertonic in Preschoolers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "7% Hypertonic Saline (HS)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Isotonic Saline (IS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington, the Collaborative Health Studies Coordinating Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "3 Years to 5 Years"
      },
      "enrollment_count": 150,
      "start_date": "2015-03-01",
      "completion_date": "2018-08-31",
      "has_results": false,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02378467"
    },
    {
      "nct_id": "NCT01552434",
      "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Castleman Disease",
        "Digestive System Carcinoma",
        "Erdheim-Chester Disease",
        "Lip and Oral Cavity Carcinoma",
        "Lymphangioleiomyomatosis",
        "Malignant Endocrine Neoplasm",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Male Reproductive System Neoplasm",
        "Malignant Neoplasm",
        "Malignant Respiratory Tract Neoplasm",
        "Malignant Thoracic Neoplasm",
        "Malignant Urinary System Neoplasm",
        "Mesothelial Neoplasm",
        "Metastatic Malignant Neoplasm",
        "Metastatic Urothelial Carcinoma",
        "Neurofibromatosis Type 2",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Digestive System Carcinoma",
        "Recurrent Female Reproductive System Carcinoma",
        "Recurrent Male Reproductive System Carcinoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Pharyngeal Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Malignant Neoplasm",
        "Soft Tissue Neoplasm",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Pharyngeal Cancer",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Pharyngeal Cancer",
        "Stage IVA Pharyngeal Cancer",
        "Stage IVB Pharyngeal Cancer",
        "Stage IVC Pharyngeal Cancer",
        "Thyroid Gland Neoplasm"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 154,
      "start_date": "2012-10-16",
      "completion_date": "2026-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552434"
    },
    {
      "nct_id": "NCT04579939",
      "title": "Oral Glucose Tolerance Testing Using Candy for Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Candy Glucose Tolerance Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "10 Years to 21 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-25",
      "completion_date": "2021-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-01-20",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04579939"
    },
    {
      "nct_id": "NCT00381628",
      "title": "Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "epithelial cells and blood lymphocyte extraction",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2006-09",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381628"
    },
    {
      "nct_id": "NCT03256799",
      "title": "Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ivacaftor/Ataluren",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-03-17",
      "completion_date": "2018-02-16",
      "has_results": true,
      "last_update_posted_date": "2019-07-19",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03256799"
    },
    {
      "nct_id": "NCT06419231",
      "title": "Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gut Health"
      ],
      "interventions": [
        {
          "name": "Butyrate Formulation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Butyrate + Polyphenol Formulation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Supplement Formulators, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 143,
      "start_date": "2023-10-31",
      "completion_date": "2025-06-18",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 1,
      "location_summary": "Fort Lauderdale, Florida",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06419231"
    },
    {
      "nct_id": "NCT01319331",
      "title": "The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes",
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Alpha 1-Antitrypsin (AAT, Aralast NP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "6 Years to 45 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-10",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-10-16T11:53:48.261Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01319331"
    }
  ]
}